DE602004021574D1 - Modulatorische verbindungen und verfahren für glutamattransport - Google Patents

Modulatorische verbindungen und verfahren für glutamattransport

Info

Publication number
DE602004021574D1
DE602004021574D1 DE602004021574T DE602004021574T DE602004021574D1 DE 602004021574 D1 DE602004021574 D1 DE 602004021574D1 DE 602004021574 T DE602004021574 T DE 602004021574T DE 602004021574 T DE602004021574 T DE 602004021574T DE 602004021574 D1 DE602004021574 D1 DE 602004021574D1
Authority
DE
Germany
Prior art keywords
glutamat
modulatory
connections
transport
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004021574T
Other languages
English (en)
Inventor
Jeffrey D Rothstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of DE602004021574D1 publication Critical patent/DE602004021574D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
DE602004021574T 2003-02-26 2004-02-25 Modulatorische verbindungen und verfahren für glutamattransport Expired - Lifetime DE602004021574D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45022703P 2003-02-26 2003-02-26
PCT/US2004/005698 WO2004076675A2 (en) 2003-02-26 2004-02-25 Glutamate transport modulatory compounds and methods

Publications (1)

Publication Number Publication Date
DE602004021574D1 true DE602004021574D1 (de) 2009-07-30

Family

ID=32927622

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004021574T Expired - Lifetime DE602004021574D1 (de) 2003-02-26 2004-02-25 Modulatorische verbindungen und verfahren für glutamattransport

Country Status (13)

Country Link
US (1) US20060121488A1 (de)
EP (1) EP1611238B1 (de)
JP (1) JP2006524637A (de)
KR (1) KR20050115245A (de)
AT (1) ATE433993T1 (de)
AU (1) AU2004214938B2 (de)
CA (1) CA2516619A1 (de)
DE (1) DE602004021574D1 (de)
DK (1) DK1611238T3 (de)
ES (1) ES2328811T3 (de)
MX (1) MXPA05009134A (de)
PL (1) PL377896A1 (de)
WO (1) WO2004076675A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506194A1 (en) 2002-11-22 2004-06-10 The Johns Hopkins University Target for therapy of cognitive impairment
US20070238717A1 (en) * 2003-10-21 2007-10-11 Johns Hopkins University Neuroprotection with Beta-Lactam Compounds
AU2006220918A1 (en) * 2005-03-04 2006-09-14 Alsgen, Inc Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues6
EP3753561A1 (de) 2005-04-05 2020-12-23 Yale University Glutamatmodulationsmittel bei der behandlung mentaler störungen
KR20080106928A (ko) * 2006-02-16 2008-12-09 더 맥클린 하스피털 코퍼레이션 파킨슨병의 치료를 위한 방법들 및 조성물들
FR2902010B1 (fr) * 2006-06-12 2008-08-22 Pierre Fabre Medicament Sa Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
WO2009033055A1 (en) * 2007-09-06 2009-03-12 Rutgers, The State University Of New Jersey Methods and kits for identification of anti-excitotoxic compounds
KR100980098B1 (ko) * 2008-01-30 2010-09-03 한국과학기술연구원 음이온 채널을 통한 신경전달물질의 방출 조절
JP5850321B2 (ja) * 2010-02-10 2016-02-03 公立大学法人横浜市立大学 神経選択的転写抑制因子ＮＲＳＦに特異的に結合するｍＳｉｎ３Ｂに結合する化合物の利用
FR2958664B1 (fr) 2010-04-07 2012-10-26 Coatex Sas Utilisation d'un latex de styrene et de taille de 100 nm comme agent rheologique dans une sauce de couchage papetiere, sauce et son procede d'obtention
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
AU2011336346B2 (en) * 2010-12-02 2015-06-18 Massachusetts Institute Of Technology Chemical and RNAi suppressors of neurotoxicity in Huntington's Disease
WO2014076702A1 (en) * 2012-11-14 2014-05-22 Ramot At Tel-Aviv University Ltd. Combination treatment for amyotrophic lateral sclerosis (als)
US10448862B2 (en) * 2013-09-06 2019-10-22 Covidien Lp System and method for light based lung visualization
CN104074095A (zh) * 2014-06-25 2014-10-01 宁波天源科技有限公司 流变改质剂
KR101809379B1 (ko) * 2016-10-13 2017-12-14 연세대학교 산학협력단 디오스민 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물
CN111116374B (zh) * 2019-12-04 2020-12-15 北京理工大学 一种氨鲁米特与2-硝基苯甲酸合成π-π键共晶体的方法
CN110923148B (zh) * 2019-12-11 2021-05-14 华北制药股份有限公司 青霉素v钾高产菌及其在发酵生产青霉素v钾中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575506A (en) * 1983-11-03 1986-03-11 Zambon S.P.A. Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics
US5210076A (en) 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
CA2087449A1 (en) * 1990-08-13 1992-02-14 Joseph L. Roba Use of heterocyclic amino-alcohol compounds for treatment of cns diseases
US5658782A (en) * 1993-10-20 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization Amino acid transporters and uses
US5795563A (en) * 1996-09-04 1998-08-18 Sphingomonas Research Partners, L.P. Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment
US6255467B1 (en) * 1997-11-06 2001-07-03 Pathobiotek Diagnostics Inc. Human blood bacterium
US7060457B2 (en) * 1998-03-18 2006-06-13 Johns Hopkins University Aberrant glutamate transporters and methods of use
WO1999059964A1 (en) * 1998-05-15 1999-11-25 University Of Vermont Novel analogs of 16-hydroxyeicosatetraenoic acid
EP2305251A3 (de) * 1999-08-16 2011-05-18 Revaax Pharmaceuticals LLC Pharmazeutische Zubereitungen die Clavulansäure oder Derivate enthalten zur Behandlung von sexuellen Störungen
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
AU2001288792A1 (en) * 2000-09-06 2002-03-22 Neurotherapeutics, Llc Method of treating neurologic disorders
US6833478B2 (en) * 2001-07-13 2004-12-21 Sri International N,N-dinitramide salts as solubilizing agents for biologically active agents
DE60325695D1 (de) * 2002-02-15 2009-02-26 Univ Johns Hopkins Der eaat2-promotor und dessen verwendung
CA2506194A1 (en) * 2002-11-22 2004-06-10 The Johns Hopkins University Target for therapy of cognitive impairment

Also Published As

Publication number Publication date
CA2516619A1 (en) 2004-09-10
EP1611238A4 (de) 2007-07-04
WO2004076675A3 (en) 2005-03-17
PL377896A1 (pl) 2006-02-20
WO2004076675A2 (en) 2004-09-10
AU2004214938A1 (en) 2004-09-10
ES2328811T3 (es) 2009-11-18
EP1611238A2 (de) 2006-01-04
JP2006524637A (ja) 2006-11-02
US20060121488A1 (en) 2006-06-08
ATE433993T1 (de) 2009-07-15
EP1611238B1 (de) 2009-06-17
AU2004214938B2 (en) 2008-11-06
DK1611238T3 (da) 2009-10-26
MXPA05009134A (es) 2005-12-05
KR20050115245A (ko) 2005-12-07

Similar Documents

Publication Publication Date Title
DE602004021574D1 (de) Modulatorische verbindungen und verfahren für glutamattransport
CY1123535T1 (el) Υποκαταστατο θεραπευτικο τελικο σημειο για βασιζομενη σε anti-ctla-4 ανοσοθεραπεια ασθενειας
WO2020102741A8 (en) Methods and compositions for protein sequencing
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
DE602005027399D1 (de) Für humane matriptase spezifische bindungsproteine
DE602004026912D1 (de) Formulierungen und verfahren zum denaturieren von proteinen
DE60237194D1 (de) Plattform für protein-profiling
ATE440860T1 (de) An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen
DE602006013143D1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
MXPA03000316A (es) Reactivos y metodos para la identificacion de agentes de enlace.
DE69618614D1 (de) NUKLEINSÄUREMOLEKÜLE MIT DER FÄHIGKEIT ZUR UNTERSCHEIDUNG VON PrPc UND PrPSc-PRIONPROTEIN-ISOFORMEN UND VERFAHREN ZU DEREN HERSTELLUNG
ATE545658T1 (de) Verfahren zur behandlung von synovialsarkom
ATE503231T1 (de) Hohlraum-induzierte allosterische modifikation von intermolekularen interaktionen und verfahren zur identifikation von verbindungen, die diese bewirken
MX2021014336A (es) Caracterizacion de variantes de carga especificas del dominio de anticuerpos.
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
PT865609E (pt) Processos para o diagnostico e terapia de carcinomas do epitelio escamoso
DK1117682T3 (da) Chi-conotoksin-peptider som inhibitorer af neuronale amintransportere
WO2023114732A3 (en) Single-molecule peptide sequencing through molecular barcoding and ex-situ analysis
DE602004016006D1 (de) Screening-verfahren
ZA202304030B (en) Modified cxcl10 for immunotherapy of cancer diseases
TR201902414A2 (tr) Dna, rna ve protei̇n di̇zi̇li̇mleri̇ni̇n yorumlanmasina yöneli̇k örüntü tanima tabanli bi̇r yöntem
EA202191168A1 (ru) Способ и система идентификации и количественного определения белка

Legal Events

Date Code Title Description
8364 No opposition during term of opposition